Hepatitis C viral infection (HCV) after injection drug use is very prevalent. The kind of genotype determines the response to treatment. However, no systematic review update on the global genotype distribution of HCV in people who inject drugs (PWID) is available at this moment.
Background and aims Methods
A systematic review was performed by using the keywords: Genotype, Hepatitis C, Injection drug user / Intravenous drug user / Substance user/ PWID, Name of countries in Pubmed, Embase and PsychInfo. 132 reports on genotyping of HCV among PWID*.
84 sources were graded lower or were within range but older, or with lower study population than sources used to generate estimates.
48 sources used to generate an estimation of the prevalence of the specific genotypes of Hepatitis C among PWID in 48 countries across 10 world regions.
Results
The most important genotype causing HCV infection in PWID globally is genotype 1, as is the case in the general population, but also genotype 3 is highly prevalent in PWID. Genotype 4 is most prevalent in Africa, spreading into Europe, whereas genotype 2 and 6 are more located in Asia. The most important difference comparing to the general population are generally lower prevalence of genotype 1b, and higher prevalence of genotype 3 in PWID. As the genotype nowadays still determines the treatment, and as there is a different genotype distribution than in the general population, it is important to identify the genotype also in PWID. Selection, grading and clarification of hepatitis reports • Hepatitis reports were restricted to serological test results for anti-HCV, HCV RNA and HCV genotyping • If hepatitis reports were available from the same sample(s) and same site(s) in multiple years, only the most recent report was selected.
• Hepatitis reports from one city were assumed to be from a single site unless otherwise stated.
• Hepatitis reports were assumed to be single site and single sample type unless otherwise stated.
• If calculation or typographical errors were detected in source documents, reports were recalculated and clarified with authors where possible.
Grade and date-based selection of reports
• If recent (2000 onwards) grade A (multi-sample multi-site) reports were available, we selected the range of these and did not select lower graded reports.
• If recent grade A reports were unavailable, we selected the range of recent reports of the next highest grade. Older reports were selected if no recent reports were available.
• Recent grade B (B1/multi-site single sample, or B2/single sample multi-site) reports were selected in preference to older grade B reports. Recent grade C reports were selected in preference to older grade B reports. Older grade C reports were selected if no grade B reports were available. Grade D reports were only used if no higher grade was available.
• Pre-2000 reports were selected only if later reports were unavailable.
Additional selection and exclusion criteria
• 'eports fro self-report studies (grade E) or unspecified methodologies (ungraded) were excluded.
• 'eports of ge etic or sali a testi g, or residue fro s ri ges ere e cluded.
• 'eports fro studies restricted to ou g PWIDs ere e cluded.
• 'eports fro studies e cludi g PWIDs of either ge der were excluded if mixed gender reports were available. 
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